Scientist I/II - Bioconjugation

The Scientist I/II - Bioconjugation will be an integral member of the Targeted Therapeutics Group focused on generating novel antibody-based therapies for the treatment of cancers. The successful candidate will contribute to the design, synthesis, characterization, and optimization of antibody-drug conjugates (ADCs), degrader-antibody conjugates (DACs), and other targeted therapeutic modalities. This position offers an exciting opportunity to work in a fast-paced multidisciplinary environment advancing innovative cancer therapeutics from discovery through preclinical development, and into clinical development.